211 related articles for article (PubMed ID: 15943041)
41. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
43. Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.
Long J; Wang Y; Li M; Tong WM; Jia JD; Huang J
Oncol Rep; 2013 Jul; 30(1):119-24. PubMed ID: 23624687
[TBL] [Abstract][Full Text] [Related]
44. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
45. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
46. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
[TBL] [Abstract][Full Text] [Related]
47. Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia.
Schlott T; Ahrens K; Ruschenburg I; Reimer S; Hartmann H; Droese M
Br J Cancer; 1999 Apr; 80(1-2):73-8. PubMed ID: 10389981
[TBL] [Abstract][Full Text] [Related]
48. Results of p53 analysis in pediatric malignancies in Poland.
Fiszer-Maliszewska Ł; Czernik J; Sawicz-Birkowska K; Kazanowska B; Wojciechowska B
Med Pediatr Oncol; 2003 May; 40(5):316-21. PubMed ID: 12652620
[TBL] [Abstract][Full Text] [Related]
49. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
50. p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver.
Kang YK; Kim CJ; Kim WH; Kim HO; Kang GH; Kim YI
Virchows Arch; 1998 Jan; 432(1):27-32. PubMed ID: 9463584
[TBL] [Abstract][Full Text] [Related]
51. Role of P53 and MDM2 in treatment response of human germ cell tumors.
Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2002 Mar; 20(6):1551-61. PubMed ID: 11896104
[TBL] [Abstract][Full Text] [Related]
52. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
53. [Involvement of WT1 gene expression in regulation of P53 and MDM2 proteins function in acute lymphoblastic leukemia].
Bartkowiak J; Wójcik I; Stankiewicz W
Pol Merkur Lekarski; 2001 Nov; 11(65):402-5. PubMed ID: 11852808
[TBL] [Abstract][Full Text] [Related]
54. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
55. Accumulation of MDM2 in pleomorphic xanthoastrocytomas.
Matsumoto K; Suzuki SO; Fukui M; Iwaki T
Pathol Int; 2004 Jun; 54(6):387-91. PubMed ID: 15144396
[TBL] [Abstract][Full Text] [Related]
56. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma: MDM2 overexpression is a common event.
Lim KP; Sharifah H; Lau SH; Teo SH; Cheong SC
Oncol Rep; 2005 Oct; 14(4):963-8. PubMed ID: 16142358
[TBL] [Abstract][Full Text] [Related]
57. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
[TBL] [Abstract][Full Text] [Related]
58. New insights into p53 protein stabilisation in oral squamous cell carcinoma.
Partridge M; Kiguwa S; Emilion G; Pateromichelakis S; A'Hern R; Langdon JD
Oral Oncol; 1999 Jan; 35(1):45-55. PubMed ID: 10211310
[TBL] [Abstract][Full Text] [Related]
59. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
60. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
